» Articles » PMID: 30880944

COPD Patients' Characteristics, Usual Care, and Adherence to Guidelines: the Greek UNLOCK Study

Overview
Publisher Dove Medical Press
Specialty Pulmonary Medicine
Date 2019 Mar 19
PMID 30880944
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: GOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CAT-and mMRC-based classification and described symptoms within groups.

Patients And Methods: A total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Physicians used structured interviews to collect cross-sectional data including demographics, symptoms, CAT, mMRC scores, and medications. Patients were classified into A-D groups based on CAT and mMRC, and prevalence of symptoms and medication was estimated within A-D groups. Interviews with physicians were also performed to explore additional issues about treatment and adherence to guidelines.

Results: Mean (SD) age was 65 (12.3) years with 79% males. The majority of patients reported uncontrolled symptoms (91% and 61% with ≥10 CAT or ≥2 mMRC scores, respectively). Thirty-seven percentage had $2 exacerbations in the past year. Group B was the largest followed by Groups D, A, and C. Patients were classified as more severe by CAT than by mMRC. In all groups, the majority were treated with combined long-acting beta agonist/ICS (> 50%). When patients were asked to report their main symptoms, dyspnea and cough were the most important symptoms mentioned, and there was a great variation between the A-D groups. However, Groups A-C reported mainly morning symptoms, whereas Group D suffered symptoms all day. Physicians reported a significant number of barriers to implementing guidelines, eg, frequent lack of guideline updates, access to diagnostic procedures, and prescription-reimbursement issues.

Conclusion: Our study confirms poor adherence to guidelines regarding treatment with an overuse of ICS and important barriers to implementation. A mismatch in classification occurs depending on the tool used, which can mislead clinicians in their choice of treatment.

Citing Articles

Factors Associated with Patient Education in Patients with Chronic Obstructive Pulmonary Disease (COPD) - A Primary Health Care Register-Based Study.

Lindh A, Giezeman M, Theander K, Zakrisson A, Westerdahl E, Stridsman C Int J Chron Obstruct Pulmon Dis. 2024; 19:1069-1077.

PMID: 38765768 PMC: 11102747. DOI: 10.2147/COPD.S455080.


Pharmaceutical treatment status of patients with COPD in the community based on medical Internet of Things: a real-world study.

Wu P, Jiang Y, Si F, Wang H, Song X, Sheng C NPJ Prim Care Respir Med. 2024; 34(1):10.

PMID: 38729942 PMC: 11087570. DOI: 10.1038/s41533-024-00371-0.


A Chronic Obstructive Pulmonary Disease Self-Management Intervention for Improving Patient-Reported Outcomes in Primary Care in Greece.

Tsaousi F, Bouloukaki I, Christodoulakis A, Ierodiakonou D, Tzanakis N, Tsiligianni I Medicina (Kaunas). 2024; 60(3).

PMID: 38541103 PMC: 10972103. DOI: 10.3390/medicina60030377.


National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018.

Klitgaard A, Ibsen R, Lykkegaard J, Hilberg O, Lokke A Biomedicines. 2024; 12(2).

PMID: 38397973 PMC: 10886715. DOI: 10.3390/biomedicines12020372.


Greek Guidelines for the Management of COPD, a Proposal of a Holistic Approach Based on the needs of the Greek Community.

Tzanakis N, Kosmas E, Papaioannou A, Hillas G, Zervas E, Loukides S J Pers Med. 2022; 12(12).

PMID: 36556218 PMC: 9788491. DOI: 10.3390/jpm12121997.


References
1.
Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J . Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999; 54(7):581-6. PMC: 1745516. DOI: 10.1136/thx.54.7.581. View

2.
Miravitlles M, Mayordomo C, Artes M, Nicolau F, Segu J . Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. Respir Med. 1999; 93(3):173-9. DOI: 10.1016/s0954-6111(99)90004-5. View

3.
Roche N, Lepage T, Bourcereau J, Terrioux P . Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2002; 18(6):903-8. DOI: 10.1183/09031936.01.00213701. View

4.
Rennard S, Decramer M, Calverley P, Pride N, Soriano J, Vermeire P . Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002; 20(4):799-805. DOI: 10.1183/09031936.02.03242002. View

5.
Decramer M, Bartsch P, Pauwels R, Yernault J . Management of COPD according to guidelines. A national survey among Belgian physicians. Monaldi Arch Chest Dis. 2003; 59(1):62-80. View